Serum Cystatin C in Early Diabetic Nephropathy Diagnosis and Treatment

Objective To explore the detection and therapeutic efficiency of Serum Cystatin C(CysC) in early diagnosis of type 2 diabetic nephropathy.Method 160 cases with 2 type diabetes mellitus in March,2009 to September,2011 in the endocrine division of Wuchang Hospital of Wuhan City were chosen to detecte the serum CysC.At the same time,urine during 24 hours was collected from the patients to determine urinary microalbumin.160 patients were divided into 2 groups accordng to urinary microalbumin excretion rate(Urea) during 24 hours:simple type 2 diabetic group(Urea 330 mg/24h) and early diabetic nephropathy group(Urea 30~300 mg/24h).30 healthy cases in the medical center of Wuchang Hospital were taken as control group,and the serum concentrations of CysC and Urea in the groups were analyzed.After treatment with intensive blood glucose control and candesartan 4 mg/d for 8 weeks,the CysC and Urea in the early diabetic nephropathy group was measured again.Results The differences was not significant between control group and simple type 2 diabetes group(P0.05);in the early diabetic nephropathy group,serum CysC concentrations elevated and was greater than those in simple type 2 diabetes group and the control group(P0.05),the difference was statistically significant.After intensive blood glucose control and candesartan treatment,CysC and Urea in the early diabetic nephropathy group were significantly decreased(P0.05),the difference was statistically significant.Conclusion CysC is the ideal marker of glomerular filtration rate and the ideal index in early evaluation of diabetic nephropathy.Intensive blood glucose control and candesartan can significantly reduce the blood CysC and Urea in early diabetic nephropathy and CysC is also the ideal index of efficacy evaluation of early diabetic nephropathy.